/PRNewswire/ Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that.
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that.
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients
42% change in treatment recommendations when using DCISionRT
News provided by
Share this article
Share this article
LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT on clinicians recommendations to administer or omit adjuvant radiotherapy (RT) in patients with DCIS (ductal carcinoma in situ) following breast conserving surgery (BCS). Data published today in the
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.